ymimwr | Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/32ymimwr_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/32ymimwr_hasAnnotation_C1422064> <https://research.tib.eu/covid-19/entity/32ymimwr_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Fu%2C_Wenyu%3B_Chen%2C_Yujianan%3B_Wang%2C_Kaidi%3B_Hettinghouse%2C_Aubryanna%3B_Hu%2C_Wenhuo%3B_Wang%2C_Jing-Quan%3B_Lei%2C_Zi-Ning%3B_Chen%2C_Zhe-Sheng%3B_Stapleford%2C_Kenneth_A%3B_Liu%2C_Chuan-Ju>
?:journal	Protein_Cell_(Online)
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/32ymimwr_HAS_C0013227_INTERACTS_WITH_C1422064> <https://research.tib.eu/covid-19/entity/32ymimwr_HAS_C0013227_TREATS_C5203676>
?:source	WHO
?:title	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#932657
?:year	2020

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/32ymimwr>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/32ymimwr>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all